B. Öberg

1.9k total citations
67 papers, 1.6k citations indexed

About

B. Öberg is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, B. Öberg has authored 67 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Infectious Diseases, 32 papers in Epidemiology and 22 papers in Molecular Biology. Recurrent topics in B. Öberg's work include HIV/AIDS drug development and treatment (29 papers), HIV Research and Treatment (18 papers) and Herpesvirus Infections and Treatments (13 papers). B. Öberg is often cited by papers focused on HIV/AIDS drug development and treatment (29 papers), HIV Research and Treatment (18 papers) and Herpesvirus Infections and Treatments (13 papers). B. Öberg collaborates with scholars based in Sweden, United States and Australia. B. Öberg's co-authors include Lennart Philipson, Lotta Vrang, Anna‐Karin Larsson, José L. Saborío, Nils‐Gunnar Johansson, D Böttiger, Bo Sundquist, S. Alenius, Erik Helgstrand and Elisabeth Ståhle and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Hepatology.

In The Last Decade

B. Öberg

64 papers receiving 1.4k citations

Peers

Countries citing papers authored by B. Öberg

Since Specialization

Citations

This map shows the geographic impact of B. Öberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Öberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Öberg more than expected).

Fields of papers citing papers by B. Öberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Öberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Öberg. The network helps show where B. Öberg may publish in the future.

Co-authorship network of co-authors of B. Öberg

This figure shows the co-authorship network connecting the top 25 collaborators of B. Öberg. A scholar is included among the top collaborators of B. Öberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Öberg. B. Öberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cancer decentralized clinical trials in the Veterans Health Administration 2025 ·JNCI Journal of the National Cancer Institute ·Daphne R. Friedman, (unknown), (unknown), Zachary Burningham, (unknown), (unknown), (unknown), (unknown), José Gil Martínez, Tiffany M. Stewart, (unknown), (unknown), (unknown), B. Öberg, Michael J. Kelley	0
2	Abstract 919: Veterans Health Administration: Decentralized clinical trials 2024 ·Cancer Research ·(unknown), (unknown), (unknown), Zachary Burningham, (unknown), Tiffany M. Stewart, B. Öberg, (unknown), (unknown), (unknown), (unknown), (unknown), Michael J. Kelley, Daphne R. Friedman	0
3	Prevention of Ulcerative Lesions by Episodic Treatment of Recurrent Herpes Labialis: A Literature Review 2010 ·Acta Dermato Venereologica ·Johan Harmenberg, B. Öberg, Spotswood L. Spruance	37
4	MIV-170, a Novel NNRTI With Potent Activity Against HIV and HIV Mutants 2008 ·Antiviral Research ·B. Öberg, (unknown), Christer Sahlberg, Bertil Samuelsson, Kristina Wikström, Lotta Vrang, Han Zhang	1
5	PCV82 FACTORS INFLUENCING COMPLIANCE WITH COMBINATION ANTIHYPERTENSIVE PHARMACOTHERAPY IN A LARGE US DATABASE 2007 ·Value in Health ·(unknown), (unknown), B. Öberg, A. Keskinaslan, (unknown)	1
6	Inhibition of SIV and HIV-2 Replication in Cynomolgus Monkeys by (-)9-[4-Hydroxy-2-(Hydroxymethyl)-Butyl]Guanine (H2G) 1996 ·Antiviral chemistry & chemotherapy ·D Böttiger, Nils Gunnar Johansson, Peter Lind, (unknown), (unknown), Per Putkonen, Lotta Vrang, Britta Wahrén, B. Öberg	1
7	Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. 1995 ·Proceedings of the National Academy of Sciences ·Klaus Überla, Christiane Stahl‐Hennig, D Böttiger, Kerstin Mätz‐Rensing, F.‐J. Kaup, (unknown), W A Haseltine, B Fleckenstein, Gerhard Hunsmann, B. Öberg	104
8	Efficacy of (-)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in African green monkeys infected with simian varicella virus 1993 ·Antimicrobial Agents and Chemotherapy ·Kenneth F. Soike, (unknown), (unknown), B. Öberg	19
9	51 Inhibition of HIV-1 RNase H by the non-nucleoside RT inhibitors 9-CL tibo and L-697, 661 1993 ·Antiviral Research ·(unknown), Kristina Bäckbro, Torsten Unge, Ramagauri Bhikhabhai, B. Strandberg, B. Öberg	1
10	Antiviral effects of 3'-fluorothymidine and 3'-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. 1991 ·PubMed ·Bettina Lundgren, D Böttiger, (unknown), Erling Norrby, Elisabeth Ståhle, Britta Wahrén, B. Öberg	39
11	Screening for new agents 1990 ·European Journal of Clinical Microbiology & Infectious Diseases ·B. Öberg, Lotta Vrang	1
12	Acute Infection of Cynomolgus Monkeys with Simian Immunodeficiency Virus (SIV_SM) as a Model to Evaluate Antiviral Compounds. Effects of 3′-Azido, 3′-Deoxythymidine, Foscarnet and 2′,3′-Dideoxycytidine 1990 ·Antiviral chemistry & chemotherapy ·Bettina Lundgren, (unknown), D Böttiger, Reinhold Benthin, (unknown), Erling Norrby, Per Putkonen, Britta Wahrén, B. Öberg	16
13	Inhibition of RNA- and DNA-dependent duck hepatitis B virus DNA polymerase activity by nucleoside and pyrophosphate analogs 1989 ·Antiviral Research ·(unknown), E Nordenfelt, B. Öberg	19
14	Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir 1986 ·Antimicrobial Agents and Chemotherapy ·Anna‐Karin Larsson, K Stenberg, A.‐C. Ericson, U Haglund, W. Yisak, Nils‐Gunnar Johansson, B. Öberg, R. Datema	70
15	Crystal and Molecular Structure of 19,20-epoxy-15-hydroxy-icajine. 1985 ·Acta chemica Scandinavica/Acta chemica Scandinavica. B, Organic chemistry and biochemistry/Acta chemica Scandinavica. A, Physical and inorganic chemistry/Acta chemica Scandinavica. Series B. Organic chemistry and biochemistry/Acta chemica Scandinavica. Series A, Physical and inorganic chemistry ·Arvid Mostad, Helle B. Mostad, Chr. Rømming, B. Öberg, R. Datema, Jyoti Chattopadhyaya	3
16	Antiherpes effects and pharmacokinetic properties of 9-(4-hydroxybutyl) guanine and the (R) and (S) enantiomers of 9-(3,4-dihydroxybutyl)guanine 1985 ·Antimicrobial Agents and Chemotherapy ·A.‐C. Ericson, Anna‐Karin Larsson, F. Y. Aoki, W. Yisak, Nils‐Gunnar Johansson, B. Öberg, R. Datema	28
17	Therapeutic Effects of Foscarnet Sodium and Acyclovir on Cutaneous Infections Due to Herpes Simplex Virus Type 1 in Guinea Pigs 1982 ·The Journal of Infectious Diseases ·S. Alenius, M Berg, (unknown), (unknown), (unknown), B. Öberg	34
18	Inhibition of hepatitis B Dane particle DNA polymerase activity by pyro-phosphate analogs. 1980 ·Apmis ·E Nordenfelt, B. Öberg, Erik Helgstrand, Earl K. Miller	13
19	Identification of the in vitro translation products of adenovirus mRNA by immunoprecipitation 1975 ·Journal of Virology ·B. Öberg, José L. Saborío, Torgny Persson, Einar Everitt, Lennart Philipson	49
20	X-Ray Diffraction Studies of the Structure of Satellite Tobacco Necrosis Virus 1972 ·Cold Spring Harbor Symposia on Quantitative Biology ·(unknown), B. Strandberg, Michael G. Rossmann, (unknown), K. Fridborg, (unknown), K. K. Kannan, Seved Lövgren, (unknown), B. Öberg, David Eaker, Stellan Hjertén, (unknown), (unknown)	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact